Parkinson's Disease: key endpoint results by drug

The key endpoints of Parkinson's Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Parkinson's Disease page.

OFF time, change

OFF time, change in Parkinson's Disease: 10 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
foslevodopa/foscarbidopa-2.8-1.0 (LD/CD)—wk 12 · n 47NCT04380142 Phase 3, secondary
istradefylline44.2−0.220 mg/Day · wk 12 · n 194NCT01968031 Phase 3, primary
Levodopa-carbidopa intestinal gel-4.0-2.1 (Levodopa-Carbidopa Capsules)—wk 12 · n 35NCT00357994 Phase 3, primary
Levodopa/carbidopa (ND0612)-2.1-1.4−0.7wk 2 · n 19NCT01883505 Phase 2, secondary
Perampanel-2.1-1.3−0.8wk 10 · n 15NCT00165789 Phase 2, secondary
Rasagiline (Azilect)-1.3-0.8−0.5wk 16 · n 158NCT01479530 Phase 3, primary
rotigotine-2.1-0.7−1.4wk 12 · n 54NCT01628848 Phase 2, secondary
Safinamide-1.9-0.9−1wk 16 · n 151NCT03881371 Phase 3, primary
Solengepras (CVN424)-1.6-0.5−1.1150 mg · wk 4 · n 44NCT04191577 Phase 2, secondary
Tavapadon-1.6-0.9−0.8wk 11 · n 242NCT04542499 Phase 3, secondary

Drugs checked with no result here: 7 trial running, 18 not reported, 7 not posted.

ON time without troublesome dyskinesia, change

ON time without troublesome dyskinesia, change in Parkinson's Disease: 5 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Amantadine ER (Gocovri/ADS-5102)3.60.9+2.7420 mg · wk 8 · n 19NCT01397422 Phase 2/3, secondary
foslevodopa/foscarbidopa2.71.0 (LD/CD)—wk 12 · n 47NCT04380142 Phase 3, primary
istradefylline10.710.1+0.620 mg/Day · wk 12 · n 194NCT01968031 Phase 3, secondary
Levodopa-carbidopa intestinal gel4.12.2 (Levodopa-Carbidopa Capsules)—wk 12 · n 35NCT00357994 Phase 3, secondary
Tavapadon1.70.6+1.1wk 26 · n 153NCT04542499 Phase 3, primary

Drugs checked with no result here: 9 trial running, 17 not reported, 11 not posted.

UPDRS Part III, change

UPDRS Part III, change in Parkinson's Disease: 7 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
istradefylline19.719.4+0.320 mg/Day · wk 12 · n 194NCT01968031 Phase 3, secondary
Levodopa (Inbrija)-9.8-5.9−3.9wk 12 · n 114NCT02240030 Phase 3, primary
Levodopa-carbidopa intestinal gel-1.5-2.9 (Levodopa-Carbidopa Capsules)—wk 12 · n 36NCT00357994 Phase 3, secondary
Pramipexole-10.2-9.9 (Pramipexole IR)—wk 12 · n 56NCT00560508 Phase 2/3, secondary
Pramipexole ER (Mirapex ER)-8.3-4.3−4wk 18 · n 161NCT00466167 Phase 3, secondary
rotigotine-10.9-4.5−6.4wk 16 · n 164NCT01628926 Phase 3, primary
Rytary (IPX066)21.625.5 (IR CD-LD)—wk 0 · n 27NCT00869791 Phase 2, secondary

Drugs checked with no result here: 9 trial running, 15 not reported, 11 not posted.

MDS-UPDRS Part II, change

MDS-UPDRS Part II, change in Parkinson's Disease: 5 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Buntanetap-0.0-0.1+0.120 mg · n 152NCT05357989 Phase 3, primary
foslevodopa/foscarbidopa-2.6-1.1 (LD/CD)—wk 12 · n 46NCT04380142 Phase 3, secondary
Rasagiline (Azilect)0.12.3−2.21 mg · wk 26 · n 116NCT02337725 Phase 3, secondary
Solengepras (CVN424)-0.30−0.3150 mg · wk 12 · n 32NCT06006247 Phase 2, secondary
Tavapadon-1.70.9−2.615 mg · wk 26 · n 116NCT04201093 Phase 3, secondary

Drugs checked with no result here: 18 not reported, 7 trial running, 12 not posted.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 42 approved or late-stage drugs with a featured trial in Parkinson's Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.